A Professional master’s degree that will allow you to keep updated on the latest scientific findings in Oncohematology and the paradigm shift that they are producing"

The recent scientific literature on the etiopathogenesis of acute lymphoblastic leukemias, the routine management of oncohematological diseases or clinical trials in their various phases open up a world of possibilities in patient care and survival.

Therefore, being aware of the latest evidence on treatment alternatives in relapsed or refractory cases, as well as the most recommended tests for aggressive lymphomas or Hodgkin's lymphomas are key to the daily practice of medical professionals. In this line, TECH has designed a 100% online degree that covers over 12 months, the most rigorous and current information in Oncohematology.

This is an intensive program, taught by experts with national and international recognition, who transfer in this Professional master’s degree, the most advanced content on diagnostic procedures and various therapies to address the most common pathologies. All of this, is supported by innovative pedagogical tools based on video summaries, detailed videos, specialized readings and case studies.

In addition, thanks to the Relearning system, based on the continuous repetition continually of key concepts, the alumni will be able to strengthen them in a simple way and reduce the long hours of study and memorization.

So, without the need for classroom attendance or classes with restricted schedules, the specialist has greater freedom to self-manage his or her study time and to access the syllabus hosted on the virtual platform. You only need an electronic device with an Internet connection to visualize the content, wherever and whenever you need. A unique opportunity that only TECH, the world's largest digital university, can offer.

Get a complete update of your knowledge in Oncohematology from real experts in the field"

This Professional master’s degree in Oncohematology contains the most complete and up-to-date scientific program on the market. Its most outstanding features are:

• The development of practical casese presented by experts in Hematology and Hemotherapy
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where self-assessment can be used to improve learning
• Its special emphasis on innovative methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

Thanks to this university degree you will be updated on the latest treatments used for patients with Acute Myeloid Leukemia"

The program’s teaching staff includes professionals from sector who contribute their work experience to this educational program, as well as renowned specialists from leading societies and prestigious universities.

Its multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide an immersive education programmed to learn in real situations.

The design of this program focuses on Problem-Based Learning, by means of which the professional must try to solve the different professional practice situations that are presented throughout the academic course. For this purpose, the student will be assisted by an innovative interactive video system created by renowned experts.

Delves into the latest clinical trials around new drugs to manage MDS"

TECH suits you and that's why it offers you a flexible and 100% online Professional master’s degree"

The syllabus of this Professional master’s degree brings together in 1,500 teaching hours the most updated content on Oncohematology. In this way, the graduate will be able to delve into the latest scientific evidence on the diagnosis and pharmacological treatments of myelodysplastic syndromes, invasive fungal infections, leukemia or complications arising from allogeneic transplantation of hemopoietic progenitors. An academic itinerary in which, in addition, students will have at their disposal innovative didactic material, accessible 24 hours a day, 7 days a week.

A syllabus with a theoretical-practical perspective on the approach to the main oncohematological pathologies"

Module 1. Myelodysplastic Syndromes

1.1. General Aspects

1.1.1. Pathogenesis. CHIP, CCUS, ICUS
1.1.2. Epidemiology. Clinical Symptoms
1.1.3. Novo SMD vs. Secondary to treatment

1.2. Diagnosis

1.2.1. Cytology
1.2.2. Genetic and molecular alterations
1.2.3. Flow Cytometry

1.3. Classification. MDS/NMP

1.3.1. WHO
1.3.2. Chronic Heart Failure (CHF)
1.3.3. MDS/NMP

1.4. Prognostic indices

1.4.1. IPSS
1.4.2. IPSS-R
1.4.3. Molecular IPSS

1.5. Management of low-risk MDS

1.5.1. Use of erythropoietic stimulants
1.5.2. Iron chelating agents
1.5.3. MDS del(5q). Lenalidomide
1.5.4. Hypoplastic MDS

1.6. New medications in low-risk MDS

1.6.1. Luspatercept
1.6.2. Pharmaceuticals under development

1.7. Treatment of High-risk MDS

1.7.1. Hypomethylating agents
1.7.2. Intensive chemotherapy

1.8. New Drugs in SMD

1.8.1. Venetoclax plus hypomethylating agents
1.8.2. IDH1/IDH2 Inhibitors, Imetelstat and others

1.9. TPH in SMD

1.9.1. Indications
1.9.2. Modalities and conditioning

1.10. Role of comorbidities and geriatric assessment

1.10.1. Comorbidity scales
1.10.2. Quality of life Assessment
1.10.3. Patient-reported outcomes

Module 2. Chronic myeloproliferative neoplasms

2.1. Chronic Myeloid Leukemia. Examination and Clinical

2.1.1. Introduction. Epidemiology
2.1.2. Pathogenesis Diagnosis
2.1.3. Prognosis

2.2. LMC, Differential Diagnosis

2.2.1. Leukemoid reaction
2.2.2. LMMC
2.2.3. Atypical CML, CNL and others

2.3. CML. Treatment

2.3.1. Tirosin Kinasa Inhibitor. Imatinib
2.3.2. Second-generation TKi. Nilotinib. Dasatinib. Bosutinib
2.3.3. Other TKIs: Ponatinib. Asciminib
2.3.4. Other treatments TPH Role

2.4. Polycythemia Vera

2.4.1. Diagnosis and clinical
2.4.2. Criterios OMS. Differential Diagnosis
2.4.3. Prognosis. Low Risk Adated Treatment

2.5. High-risk polycythemia Vera, treatment

2.5.1. Initial cytoreduction options
2.5.2. Rescue options
2.5.3. Pregnancy Transformation

2.6. Essential Thrombocythemia

2.6.1. Diagnosis and clinical
2.6.2. WHO Criteria
2.6.3. Differential Diagnosis

2.7. Essential Thrombocythemia: prognosis and treatment

2.7.1. Prognosis
2.7.2. Cytoreduction indications
2.7.3. Hydroxyurea vs. Anagrelide

2.8. Primary Myelofibrosis

2.8.1. Clinical Pathogenesis
2.8.2. Diagnosis. WHO Criteria
2.8.3. Prognosis Scales

2.9. Myelofibrosis Treatment

2.9.1. Anemia management
2.9.2. JAK Inhibitors
2.9.3. New Drugs in Myelofibrosis

2.10. TPH in Myelofibrosis

2.10.1. TPH candidate selection
2.10.2. MF conditioning

Module 3. Chronic Lymphocytic Leukemia

3.1. Diagnosis

3.1.1. Etiopathogenesis
3.1.2. Complementary Tests
3.1.3. Treatment Indications

3.2. Prognosis

3.2.1. Prognostic Factors and predictive
3.2.2. Prognostic indices

3.3. Role of comorbidities and geriatric Assessment

3.3.1. Comorbidity scales
3.3.2. Geriatric Scores
3.3.3. Quality of life questionnaires. PROMs

3.4. First-Line Treatment

3.4.1. Immunochemotherapy
3.4.2. BTK Inhibitors
3.4.3. Bcl2 inhibitor. Combinations

3.5. Relapse/refractory treatment

3.5.1. Algorithms
3.5.2. Treatment sequencing
3.5.3. Role of TPH in CLL

3.6. Practical handling of BTKi

3.6.1. Hemorrhagic complications
3.6.2. Cardiovascular Complications
3.6.3. Other toxicities

3.7. Practical handling of Venetoclax

3.7.1. SLT risk assessment and prophylaxis
3.7.2. Cytopenias management

3.8. COVID and LLC

3.8.1. Antivirals Treatment Indications
3.8.2. Pre-exposure prophylaxis indications
3.8.3. Other recommendations and vaccinations in CLL

3.9. Richter's syndrome

3.9.1. Pathogenesis and clinical
3.9.2. LDCG and LH. Clonal relation
3.9.3. Treatment Options

3.10. New Drugs in LLC

3.10.1. New BTKi
3.10.2. Other drugs under development
3.10.3. CAR T at LLC

Module 4. Aggressive lymphomas

4.1. Epidemiology, clinical and pathogenesis of diffuse large B-cell lymphoma (DLBCL)

4.1.1. Epidemiology and Clinical
4.1.2. Morphology and phenotype
4.1.3. Genetic and molecular alterations

4.2. Diagnosis of LDCG

4.2.1. Molecular subtypes, cell of origin
4.2.2. Differential Diagnosis
4.2.3. Sub-entities. OMS Classification

4.3. Initial treatment of LDCG

4.3.1. Preliminary Assessment IPI
4.3.2. Limitations of alternatives to R-CHOP
4.3.3. CNS prophylaxis

4.4. 2L treatment in LDCG

4.4.1. Preliminary Assessment
4.4.2. Second line schemes
4.4.3. autologous HSCT

4.5. Treatment after second relapse

4.5.1. Preliminary Assessment
4.5.2. CAR T. Axi-cel. Liso-cel. Tisa-cel
4.5.3. Antibodies: tafasitamab, polatuzumab, loncastuximab

4.6. Burkitt/Burkitt similar

4.6.1. Etiopathogenesis., Diagnosis and Prognosis
4.6.2. Treatment of 1L
4.6.3. R/R treatment

4.7. Mantle lymphoma

4.7.1. Etiopathogenesis., Diagnosis and Prognosis
4.7.2. Treatment of 1L
4.7.3. R/R treatment

4.8. Peripheral T Lymphomas

4.8.1. Epidemiology and Clinical
4.8.2. Diagnosis. Differential Diagnosis
4.8.3. Treatment

4.9. Anaplastic lymphomas

4.9.1. Epidemiology , Pathogenesis and Clinical
4.9.2. Diagnosis and Prognosis
4.9.3. Treatment

4.10. Angioimmunoblastic T-cell lymphoma

4.10.1. Epidemiology and Clinical
4.10.2. Diagnosis
4.10.3. Treatment

Module 5. Hodgkin's and indolent lymphomas

5.1. Follicular lymphoma: diagnosis and prognosis

5.1.1. Etiopathogenesis
5.1.2. Diagnosis
5.1.3. Prognosis

5.2. Follicular Lymphoma: treatment

5.2.1. Treatment of 1L
5.2.2. R/R treatment

5.3. Nodal marginal lymphomas

5.3.1. Etiopathogenesis., Diagnosis and Prognosis
5.3.2. Treatment

5.4. Extraganglionic marginal lymphomas

5.4.1. Etiopathogenesis. Diagnosis and Prognosis
5.4.2. Treatment

5.5. Waldenström's Macroglobulinemia

5.5.1. Etiopathogenesis. Diagnosis and Prognosis
5.5.2. Treatment

5.6. Tricholeukemia

5.6.1. Etiopathogenesis. Diagnosis and Prognosis
5.6.2. Treatment

5.7. Large Granular Lymphocyte Leukemia

5.7.1. Diagnosis. Differential Diagnosis
5.7.2. Treatment

5.8. Classical Hodgkin's lymphoma: diagnosis and prognosis

5.8.1. Pathogenesis
5.8.2. Diagnosis
5.8.3. Prognosis

5.9. Classical Hodgkin's lymphoma: treatment

5.9.1. Treatment of 1L
5.9.2. R/R treatment

5.10. Hodgkin's Lymphoma subtype Lymphocytic Predominance

5.10.1. Etiopathogenesis. Diagnosis and Prognosis
5.10.2. Treatment

Module 6. Multiple myeloma and primary amyloidosis

6.1. Monoclonal Gammopathy of Uncertain Significance

6.1.1. Low- and High- Degrees GMSI
6.1.2. Recommended evaluations
6.1.3. GM of renal and other significance

6.2. Multiple Myeloma (MM) Etiopathogenesis., Diagnosis and Prognosis

6.2.1. Diagnostic Criteria
6.2.2. Genetic Alterations
6.2.3. Prognostic indices

6.3. Treatment Indications

6.3.1. WHO Criteria
6.3.2. Quiescent MM

6.4. MM First in Line Treatment

6.4.1. Suitability for TASPE in 1L
6.4.2. Types of drugs
6.4.3. Recommended combinations

6.5. Relapse/refractory treatment

6.5.1. General Considerations. Treatment Indications
6.5.2. Available Drugs
6.5.3. Algorithms or possible sequences

6.6. New Treatments in MM

6.6.1. Anti-BCMA antibody conjugates
6.6.2. Bispecific anti BCMA antibodies
6.6.3. Others: elotuzumab, selinexor

6.7. CAR T at mm

6.7.1. Cilta-cel
6.7.2. Ide-cel

6.8. Primary Amyloidosis. Diagnosis and Prognosis

6.8.1. Etiopathogenesis
6.8.2. Diagnosis
6.8.3. Prognosis

6.9. Primary Amyloidosis. Treatment

6.9.1. AutoTPH role
6.9.2. Alkylators and proteosome inhibitors
6.9.3. Role of antiCD38 antibodies

6.10. Treatment goals in MM/AL

6.10.1. Methodological limitations in the literature
6.10.2. Validation of survival surrogate variables

Module 7. Allogeneic transplant of hemopoietic progenitors

7.1. Modalidades de TPH

7.1.1. HLA-identical sibling TPH
7.1.2. DnE TPH
7.1.3. Haploidentical TPH

7.2. Pre-HPT evaluation

7.2.1. Complementary Tests
7.2.2. Fertility Preservation
7.2.3. Risk assessment for TPH

7.3. Ideal donor Selection

7.3.1. Age. Possible differences in HLA
7.3.2. CMV status. Group/Rh compatibility
7.3.3. Comorbidities. Logistical issues

7.4. Some early complications of PHPT

7.4.1. Cytopenias, bleeding, infections
7.4.2. Thrombotic Microangiopathy
7.4.3. Mucositis. Diarrhea

7.5. Other possible complications of HSCT

7.5.1. Graft Failure
7.5.2. Graft syndrome

7.6. Sinusoidal Obstruction Syndrome

7.6.1. Etiopathogenesis and diagnosis
7.6.2. Prognosis and Treatment

7.7. Acute graft-versus-recipient disease

7.7.1. Acute RHD: pathogenesis and clinic
7.7.2. Prophylaxis of RICDs
7.7.3. Acute RCRD: diagnosis and grades

7.8. Treatment of ARCI

7.8.1. Management of corticosteroids
7.8.2. Options after glucocorticoid failure

7.9. Chronic graft-versus-recipient disease

7.9.1. cRHD: pathogenesis and clinic
7.9.2. cRHD: pathogenesis and clinic get reference

7.10. Treatment of ARCI

7.10.1. Localized treatments
7.10.2. Systemic treatment options in steroid-refractory patients

Module 8. Acute Myeloid Leukemia

8.1. Clinical Symptoms

8.1.1. Introduction and Epidemiology
8.1.2. Clinical Manifestations
8.1.3. Analytical alterations

8.2. Diagnosis

8.2.1. Pathogenesis
8.2.2. Cytology
8.2.3. Flow Cytometry

8.3. Genetic and molecular alterations. Rankings and forecasts

8.3.1. Cytogenetics
8.3.2. Brain Tumor
8.3.3. WHO vs. Chronic Heart Failure (CHF)
8.3.4. Risk according to ELN

8.4. Acute promyelocytic Leukemia

8.4.1. Diagnosis
8.4.2. Prognosis
8.4.3. Treatment

8.5. LAM Intensive treatment

8.5.1. Intensive induction chemotherapy
8.5.2. 3+7 alternatives and modifications
8.5.3. Post-remission treatment

8.6. Other treatments available at LAM

8.6.1. Gemtuzumab ozogamicin
8.6.2. Liposomal formulation dauno+citarabine

8.7. Lower intensity treatments

8.7.1. Hypomethylating agents
8.7.2. Venetoclax
8.7.3. Other targeted treatments

8.8. New drugs in development

8.8.1. New promising Targets
8.8.2. Cell Therapy

8.9. TPH at LAM

8.9.1. Possible indications of autologous and allogeneic
8.9.2. TPH alo's conditioning in LAM
8.9.3. Donor Lymphocyte Infusion
8.9.4. Seconds TPH IN LAM

8.10. Management of long survivors

8.10.1. Follow-up recommendations
8.10.2. Late relapses
8.10.3. Second neoplasms and other complications

Module 9. Acute Lymphoblastic Leukemia

9.1. Epidemiology and pathogenesis

9.1.1. Epidemiology
9.1.2. Pathogenesis
9.1.3. Clinical Symptoms

9.2. Diagnosis

9.2.1. Cytology and flow cytometry
9.2.2. Cytology and flow cytometry
9.2.3. OMS Classification

9.3. Teenagers and young adults

9.3.1. Pediatric protocols
9.3.2. Management in Adult vs. Pediatricis

9.4. Prognosis

9.4.1. Poor Prognosis Factors
9.4.2. Risk Stratification
9.4.3. Role of minimal residual disease

9.5. Induction treatment

9.5.1. Role of vinca alkaloids, anthracyclines and steroids
9.5.2. Role of asparaginase and its varieties
9.5.3. CNS prophylaxis

9.6. Post-remission treatment

9.6.1. CR and EMR concept
9.6.2. Consolidations: high dose MTX management
9.6.3. Consolidations: role of Ara C and re-inductions
9.6.4. Maintenance

9.7. Allogeneic HSCT in LAL in 1L

9.7.1. Levels of limit Evidence
9.7.2. UK/ECOG study
9.7.3. Rescue chemotherapy

9.8. Relapse/refractory treatment

9.8.1. Rescue chemotherapy
9.8.2. Bispecific or conjugated antibodies
9.8.3. Cell therapy, CAR T

9.9. LAL Ph+

9.9.1. Pathogenesis and diagnosis
9.9.2. Treatment protocols including TKIs
9.9.3. Role of TPH, and of bispecific or conjugated Ac
9.9.4. LAL Ph+ Like

9.10. T-cell LAL

9.10.1. Epidemiology and pathogenesis
9.10.2. Diagnosis and Prognosis
9.10.3. Treatment

Module 10. Infections in Oncohematology

10.1. Bacteria

10.1.1. Basis of empirical treatment
10.1.2. Resistant bacteria management
10.1.3. Antibiotic de-escalation

10.2. Invasive fungal infections. General Aspects

10.2.1. Prophylaxis: indications and alternatives
10.2.2. Empirical and targeted treatment
10.2.3. Possible, probable or proven IFI

10.3. Invasive aspergillosis

10.3.1. Epidemiology. Serial monitoring
10.3.2. Treatment choice
10.3.3. Primary and Secondary Prophylaxis Surgery

10.4. Invasive candidiasis

10.4.1. Epidemiology, clinical and diagnostic
10.4.2. Empirical and targeted treatment. Step-down
10.4.3. Prophylaxis Central venous catheter removal

10.5. Other fungal infections

10.5.1. Mucormycosis
10.5.2. Fusarium, Scedosporium and Lomentospora
10.5.3. Pneumocystis: diagnosis and indications for prophylaxis

10.6. Cytomegalovirus

10.6.1. Epidemiology and Diagnosis
10.6.2. Prophylaxis: indications and alternatives
10.6.3. Treatment

10.7. VVZ

10.7.1. Varicela en inmunodeprimidos
10.7.2. Shingles prophylaxis and treatment
10.7.3. Recombinant Zoster Vaccine

10.8. Adenovirus

10.8.1. Diagnosis
10.8.2. Treatment

10.9. COVID-19

10.9.1. Prognosis
10.9.2. Early treatment and pre-exposure prophylaxis
10.9.3. Treatment of severe pneumonia

10.10. Other Viruses

10.10.1. VRS
10.10.2. Influenza
10.10.3. EBV

Deepens the role of disease assessment Minimal Cytometrically or Molecularly Detectable Acute Lymphoblastic Leukemia"